•Emerging insights into TL1A biology may guide precision therapy for IBD
•The impacts of native potential probiotic cocktail to prevent or ameliorate inflammation by targeting autophagy signalling pathway
•Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut
•RELIEVE UCCD: one pathway, two diseases, and a glimpse into the future of IBD trial design
•Fraxinellone suppresses inflammatory bowel disease by targeting PINK1 and activating PINK1/Parkin-mediated mitophagy
